Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control in people with type 2 diabetes mellitus (T2DM). While oral semaglutide is not indicated for reduction of cardiovascular event risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzauskas, Gregory F, Rind, David M, Fazioli, Katherine, Chapman, Richard H, Pearson, Steven D, Hansen, Ryan N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390985/
https://www.ncbi.nlm.nih.gov/pubmed/33769850
http://dx.doi.org/10.18553/jmcp.2021.27.4.455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390985/
https://www.ncbi.nlm.nih.gov/pubmed/33769850
http://dx.doi.org/10.18553/jmcp.2021.27.4.455

Ejemplares similares